Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novartis Meningococcal B Recombinant Vaccine in At-Risk Adults
NCT01911221Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease, sponsored by Novartis. Primary endpoints: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains at Day 91, Geometric Mean Ratios Against N Meningitidis Serogroup B Strains at Day 91 and 7 more. Started Aug 2013; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01911221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01911221.